vs
Side-by-side financial comparison of CSW INDUSTRIALS, INC. (CSW) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $233.0M, roughly 1.3× CSW INDUSTRIALS, INC.). Bio-Techne runs the higher net margin — 12.8% vs 4.4%, a 8.4% gap on every dollar of revenue. On growth, CSW INDUSTRIALS, INC. posted the faster year-over-year revenue change (20.3% vs -6.4%). Over the past eight quarters, CSW INDUSTRIALS, INC.'s revenue compounded faster (5.1% CAGR vs 4.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CSW vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $233.0M | $295.9M |
| Net Profit | $10.3M | $38.0M |
| Gross Margin | 39.7% | 64.6% |
| Operating Margin | 7.4% | 18.4% |
| Net Margin | 4.4% | 12.8% |
| Revenue YoY | 20.3% | -6.4% |
| Net Profit YoY | -61.9% | 68.3% |
| EPS (diluted) | $0.62 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $233.0M | $295.9M | ||
| Q3 25 | $277.0M | — | ||
| Q2 25 | $263.6M | $317.0M | ||
| Q1 25 | $230.5M | $316.2M | ||
| Q4 24 | $193.6M | $297.0M | ||
| Q3 24 | $227.9M | $289.5M | ||
| Q2 24 | $226.2M | $306.1M | ||
| Q1 24 | $210.9M | $303.4M |
| Q4 25 | $10.3M | $38.0M | ||
| Q3 25 | $40.7M | — | ||
| Q2 25 | $40.9M | $-17.7M | ||
| Q1 25 | $35.1M | $22.6M | ||
| Q4 24 | $26.9M | $34.9M | ||
| Q3 24 | $36.1M | $33.6M | ||
| Q2 24 | $38.6M | $40.6M | ||
| Q1 24 | $31.8M | $49.1M |
| Q4 25 | 39.7% | 64.6% | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 43.8% | 62.7% | ||
| Q1 25 | 44.2% | 67.9% | ||
| Q4 24 | 41.4% | 65.3% | ||
| Q3 24 | 45.6% | 63.2% | ||
| Q2 24 | 47.5% | 66.4% | ||
| Q1 24 | 44.4% | 67.4% |
| Q4 25 | 7.4% | 18.4% | ||
| Q3 25 | 20.5% | — | ||
| Q2 25 | 20.8% | -7.5% | ||
| Q1 25 | 19.5% | 12.2% | ||
| Q4 24 | 15.3% | 16.0% | ||
| Q3 24 | 22.6% | 13.8% | ||
| Q2 24 | 24.3% | 15.0% | ||
| Q1 24 | 21.0% | 22.1% |
| Q4 25 | 4.4% | 12.8% | ||
| Q3 25 | 14.7% | — | ||
| Q2 25 | 15.5% | -5.6% | ||
| Q1 25 | 15.2% | 7.1% | ||
| Q4 24 | 13.9% | 11.7% | ||
| Q3 24 | 15.8% | 11.6% | ||
| Q2 24 | 17.1% | 13.3% | ||
| Q1 24 | 15.1% | 16.2% |
| Q4 25 | $0.62 | $0.24 | ||
| Q3 25 | $2.41 | — | ||
| Q2 25 | $2.43 | $-0.11 | ||
| Q1 25 | $2.05 | $0.14 | ||
| Q4 24 | $1.60 | $0.22 | ||
| Q3 24 | $2.26 | $0.21 | ||
| Q2 24 | $2.47 | $0.26 | ||
| Q1 24 | $2.03 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.2M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $1.1B | $2.0B |
| Total Assets | $2.3B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.2M | $172.9M | ||
| Q3 25 | $31.5M | — | ||
| Q2 25 | $38.0M | $162.2M | ||
| Q1 25 | $225.8M | $140.7M | ||
| Q4 24 | $213.8M | $177.5M | ||
| Q3 24 | $273.2M | $187.5M | ||
| Q2 24 | $18.9M | $152.9M | ||
| Q1 24 | $22.2M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | $800.1M | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | $166.0M | $389.0M |
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.1B | $2.0B | ||
| Q4 24 | $1.0B | $2.1B | ||
| Q3 24 | $1.0B | $2.1B | ||
| Q2 24 | $650.2M | $2.1B | ||
| Q1 24 | $615.7M | $2.0B |
| Q4 25 | $2.3B | $2.5B | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.4B | $2.6B | ||
| Q4 24 | $1.4B | $2.7B | ||
| Q3 24 | $1.4B | $2.7B | ||
| Q2 24 | $1.1B | $2.7B | ||
| Q1 24 | $1.0B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | 0.75× | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | 0.27× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | — |
| Free Cash FlowOCF − Capex | $22.7M | — |
| FCF MarginFCF / Revenue | 9.8% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 2.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | $162.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.9M | — | ||
| Q3 25 | $61.8M | — | ||
| Q2 25 | $60.6M | $98.2M | ||
| Q1 25 | $27.3M | $41.1M | ||
| Q4 24 | $11.6M | $84.3M | ||
| Q3 24 | $66.8M | $63.9M | ||
| Q2 24 | $62.7M | $75.5M | ||
| Q1 24 | $22.4M | $81.0M |
| Q4 25 | $22.7M | — | ||
| Q3 25 | $58.7M | — | ||
| Q2 25 | $57.7M | $93.3M | ||
| Q1 25 | $22.8M | $31.0M | ||
| Q4 24 | $8.5M | $77.5M | ||
| Q3 24 | $61.3M | $54.7M | ||
| Q2 24 | $59.6M | $57.5M | ||
| Q1 24 | $17.5M | $64.5M |
| Q4 25 | 9.8% | — | ||
| Q3 25 | 21.2% | — | ||
| Q2 25 | 21.9% | 29.4% | ||
| Q1 25 | 9.9% | 9.8% | ||
| Q4 24 | 4.4% | 26.1% | ||
| Q3 24 | 26.9% | 18.9% | ||
| Q2 24 | 26.3% | 18.8% | ||
| Q1 24 | 8.3% | 21.3% |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 2.0% | 3.2% | ||
| Q4 24 | 1.6% | 2.3% | ||
| Q3 24 | 2.4% | 3.2% | ||
| Q2 24 | 1.4% | 5.9% | ||
| Q1 24 | 2.3% | 5.4% |
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | 1.82× | ||
| Q4 24 | 0.43× | 2.42× | ||
| Q3 24 | 1.85× | 1.90× | ||
| Q2 24 | 1.62× | 1.86× | ||
| Q1 24 | 0.71× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
